Principal Financial Group
STRO icon

Principal Financial Group’s Sutro Biopharma STRO Stock Holding History

Principal Financial Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,085
Closed -$31.8K – 2400
2024
Q2 		$31.8K Sell
1,085
-780
-42% -$30.8K ﹤0.01% 2316
2024
Q1 		$105K Sell
1,865
-125
-6% -$5.52K ﹤0.01% 2267
2023
Q4 		$85.4K Sell
1,990
-225
-10% -$7.14K ﹤0.01% 2286
2023
Q3 		$76.9K Buy
2,215
+317
+17% +$13.8K ﹤0.01% 2319
2023
Q2 		$88.3K Buy
1,898
+363
+24% +$18.1K ﹤0.01% 2307
2023
Q1 		$70.9K Buy
1,535
+188
+14% +$11.9K ﹤0.01% 2341
2022
Q4 		$109K Buy
1,347
+308
+30% +$21.4K ﹤0.01% 2282
2022
Q3 		$58K Buy
+1,039
New +$61.5K ﹤0.01% 2401
2022
Q2 		– Sell
-2,663
Closed -$219K – 2637
2022
Q1 		$219K Sell
2,663
-1,114
-29% -$106K ﹤0.01% 2314
2021
Q4 		$562K Sell
3,777
-2,817
-43% -$505K ﹤0.01% 2098
2021
Q3 		$1.25M Sell
6,594
-187
-3% -$35.6K ﹤0.01% 1957
2021
Q2 		$1.26M Buy
+6,781
New +$1.33M ﹤0.01% 1997

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group's STRO Position: Q3 2024 in Review

Principal Financial Group sold out of Sutro Biopharma (STRO) in Q3 2024, closing a stake of 1,085 shares — an estimated $31.8K sold.

Principal Financial Group first reported a position in STRO in Q2 2021 and held it in 12 quarters. The position peaked at $1.26M in Q2 2021. 130 funds tracked by Wall St. Rank hold STRO as of Q3 2024.

  • Principal Financial Group reported no remaining Sutro Biopharma position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 1,085 Sutro Biopharma shares in Q3 2024, an estimated $31.8K.
  • Principal Financial Group first reported a position in Sutro Biopharma in Q2 2021 and held it in 12 quarters.
  • Principal Financial Group's Sutro Biopharma position peaked at $1.26M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.